Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Depreciation & Amortization (CF): 2011-2025

Historic Depreciation & Amortization (CF) for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to $4.6 million.

  • Enanta Pharmaceuticals' Depreciation & Amortization (CF) rose 168.06% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 96.32%. This contributed to the annual value of $4.6 million for FY2025, which is 96.32% up from last year.
  • According to the latest figures from FY2025, Enanta Pharmaceuticals' Depreciation & Amortization (CF) is $4.6 million, which was up 96.32% from $2.3 million recorded in FY2024.
  • In the past 5 years, Enanta Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $4.6 million during FY2025, and its lowest value of $2.3 million during FY2024.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $2.4 million (2023), whereas its average is $3.1 million.
  • In the last 5 years, Enanta Pharmaceuticals' Depreciation & Amortization (CF) dropped by 20.25% in 2023 and then soared by 96.32% in 2025.
  • Enanta Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $3.3 million in 2021, then decreased by 10.83% to $3.0 million in 2022, then dropped by 20.25% to $2.4 million in 2023, then declined by 1.48% to $2.3 million in 2024, then skyrocketed by 96.32% to $4.6 million in 2025.